Compare SBH & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SBH | OGN |
|---|---|---|
| Founded | 1964 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2006 | 2020 |
| Metric | SBH | OGN |
|---|---|---|
| Price | $14.14 | $6.38 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 4 |
| Target Price | ★ $17.25 | $11.75 |
| AVG Volume (30 Days) | 1.2M | ★ 3.1M |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | ★ 1.23% |
| EPS Growth | ★ 32.17 | N/A |
| EPS | 0.45 | ★ 0.72 |
| Revenue | $3,701,424,000.00 | ★ $6,216,000,000.00 |
| Revenue This Year | $2.20 | $0.42 |
| Revenue Next Year | $1.82 | $1.67 |
| P/E Ratio | $31.49 | ★ $8.99 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.54 | $6.18 |
| 52 Week High | $17.92 | $15.88 |
| Indicator | SBH | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 38.07 | 31.58 |
| Support Level | $14.10 | $6.18 |
| Resistance Level | $15.75 | $7.87 |
| Average True Range (ATR) | 0.54 | 0.22 |
| MACD | -0.16 | -0.04 |
| Stochastic Oscillator | 7.80 | 11.52 |
Sally Beauty Holdings Inc is a professional beauty-products retailer based in the United States. The company operates throughout the United States, Puerto Rico, the United Kingdom, Belgium, Canada, Chile, Mexico, Peru, France, Ireland, Spain, Germany, Netherlands, and other geographical regions. The company operates through two business segments: Sally Beauty Supply and Beauty Systems Group. The products offered by the company include hair color and care, hair dryers and hair-styling appliances, nail care, skin care, and others.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.